Australians with rare, aggressive brain cancers now have a game-changing new treatment: vorasidenib, the first in two decades to target the genetic mutations driving IDH-mutant tumors. Approved through PBS, it slashes costs to just $25 or less with a concession card, offering patients precious time and hope where options were once limited. Beyond brain cancer, PBS is expanding access to life-saving drugs for thyroid cancer, relapsed lymphoma, and children with Crohn’s disease—helping hundreds each year afford critical care that was once out of reach.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
